Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 6/20 | 0.44 |
| ▸ | ACACA | Q13085 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24364210 | 0.81 | ACACB (0.55) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL29081574 | 0.81 | ACACB (0.55) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL22734664 | 0.75 | KMT2A (0.50) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL4354977 | 0.75 | KMT2A (0.60) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL6641585 | 0.75 | KMT2A (0.60) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL4346477 | 0.75 | KMT2A (0.60) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL6641586 | 0.75 | KMT2A (0.60) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL14639532 | 0.74 | KMT2A (0.49) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL10163711 | 0.72 | KMT2A (0.56) | DRD2ACACBACACAKMT2AATM | |
| SCHEMBL14979024 | 0.72 | KMT2A (0.56) | DRD2ACACBACACAKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | DRD2 287/4885ACACB 3481/4885ACACA 2409/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | DRD2 287/4885ACACB 3481/4885ACACA 2409/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | DRD2 287/4885ACACB 3481/4885ACACA 2409/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | DRD2 287/4885ACACB 3481/4885ACACA 2409/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | DRD2 287/4885ACACB 3481/4885ACACA 2409/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | DRD2 504/4885ACACB 1309/4885ACACA 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.